Vaccine-short Africa is hopeful of getting more COVID-19 doses, as a South African pharmaceutical firm is close to being the first in Africa to distribute them for sale across the continent. U.S.-based Johnson & Johnson says it could soon grant a license to Aspen Pharmacare, Africa’s biggest drugmaker, to produce an “African COVID-19 vaccine” called Aspenovax. Aspen Pharmacare will not make its own vaccine but will package and sell the Johnson-produced vaccine as soon as early 2022. The company has a factory in South Africa from where it already distributes the Johnson & Johnson vaccine nationwide. The proposed deal will significantly boost supplies in Africa, which has suffered serious shortages of vaccines, and is facing the spread of the new omicron variant. The World Health Organization said only 3% of Africans are fully vaccinated. Strive Masiyiwa, head of the African Union’s Africa Vaccine Acquisition Task Team, said the deal will make African nations less dependent on Western governments for vaccine supplies.
SOURCE: VOA
More Stories
Tinubu Hits the Ground Running
Russian Minister Makes a Quick Stop in Nairobi
Four Men Absolved of Drug Trafficking in Liberia Disappear
Governments in Sub-Saharan Africa Struggle to Regulate the Mass Expansion of Online Gambling
Why Returns from European Countries are Hugely Unpopular in Most African Countries
A $3 billion IMF Bailout Will Not Instantly Solve Ghana’s Economic Problems
Can Kenya Successfully Establish Efficient and Affordable Smartphone Manufacturing?
How to Be a Female Politician in Africa
Egyptian Firm Unveils IoT-enabled Smartwatch
Women at the Forefront of Africa’s Peace Efforts
With ‘Banel & Adama,’ Ramata-Toulaye Sy Takes Her Place Among Cannes’ Top Names
The Lion Sleeps Tonight: One Song’s Journey from 1930s South Africa to Disney Money-Spinner